These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16729910)

  • 1. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.
    Humphrey PA; Halabi S; Picus J; Sanford B; Vogelzang NJ; Small EJ; Kantoff PW
    Clin Genitourin Cancer; 2006 Mar; 4(4):269-74. PubMed ID: 16729910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.
    Gupta A; Karakiewicz PI; Roehrborn CG; Lotan Y; Zlotta AR; Shariat SF
    Clin Cancer Res; 2008 Nov; 14(22):7385-90. PubMed ID: 19010854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
    George DJ; Halabi S; Shepard TF; Sanford B; Vogelzang NJ; Small EJ; Kantoff PW
    Clin Cancer Res; 2005 Mar; 11(5):1815-20. PubMed ID: 15756004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
    Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW
    Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.
    George DJ; Halabi S; Shepard TF; Vogelzang NJ; Hayes DF; Small EJ; Kantoff PW;
    Clin Cancer Res; 2001 Jul; 7(7):1932-6. PubMed ID: 11448906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis.
    Junbo H; Li Q; Zaide W; Yunde H
    In Vivo; 1999; 13(2):177-80. PubMed ID: 10363175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.
    Hotte SJ; Winquist EW; Stitt L; Wilson SM; Chambers AF
    Cancer; 2002 Aug; 95(3):506-12. PubMed ID: 12209742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer.
    Naughton M; Picus J; Zhu X; Catalona WJ; Vollmer RT; Humphrey PA
    J Urol; 2001 Apr; 165(4):1325-8. PubMed ID: 11257710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor HGF lacks prognostic significance in Mexican breast cancer patients.
    Pruefer FG; Unger-Saldaña K; Mohamier L; Ramírez M; Suárez J; Ramirez MT; Maldonado V; Meléndez-Zajgla J
    J Exp Clin Cancer Res; 2006 Sep; 25(3):357-64. PubMed ID: 17167976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Namba Y; Kishikawa H; Takahara S; Ichikawa Y
    Prostate Cancer Prostatic Dis; 2008; 11(3):258-63. PubMed ID: 17876341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive significance of plasma hepatocyte growth factor and carcinoembryonic antigen in non-small lung cancer after surgery.
    Fang MY; Wang SY; Zheng YB; Gong LY; Bao WL; Gu DL; Mao WM
    Eur Rev Med Pharmacol Sci; 2014; 18(3):398-403. PubMed ID: 24563441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
    D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
    Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of hepatocyte growth factor/scatter factor (HGF/SF) in seminal plasma of patients with andrological diseases.
    Depuydt CE; De Potter CR; Zalata A; Baekelandt E; Bosmans E; Comhaire FH
    J Androl; 1998; 19(2):175-82. PubMed ID: 9570740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
    Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
    Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.